GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Price-to-Tangible-Book

RenovoRx (RenovoRx) Price-to-Tangible-Book : 13.05 (As of Jun. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Price-to-Tangible-Book?

As of today (2024-06-20), RenovoRx's share price is $1.37. RenovoRx's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.11. Hence, RenovoRx's Price to Tangible Book Ratio of today is 13.05.

The historical rank and industry rank for RenovoRx's Price-to-Tangible-Book or its related term are showing as below:

RNXT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.77   Med: 3.27   Max: 1330
Current: 12.45

During the past 5 years, RenovoRx's highest Price to Tangible Book Ratio was 1330.00. The lowest was 1.77. And the median was 3.27.

RNXT's Price-to-Tangible-Book is ranked worse than
91.16% of 1210 companies
in the Biotechnology industry
Industry Median: 2.65 vs RNXT: 12.45

A closely related ratio is called PB Ratio. As of today, RenovoRx's share price is $1.37. RenovoRx's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.11. Hence, RenovoRx's P/B Ratio of today is 13.05.


RenovoRx Price-to-Tangible-Book Historical Data

The historical data trend for RenovoRx's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Price-to-Tangible-Book Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 2.82 3.47 -

RenovoRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.76 20.36 1,330.00 - 12.76

Competitive Comparison of RenovoRx's Price-to-Tangible-Book

For the Biotechnology subindustry, RenovoRx's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where RenovoRx's Price-to-Tangible-Book falls into.



RenovoRx Price-to-Tangible-Book Calculation

RenovoRx's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=1.37/0.105
=13.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


RenovoRx Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of RenovoRx's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovoRx (RenovoRx) Business Description

Traded in Other Exchanges
N/A
Address
4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.
Executives
Angela Nelms officer: Chief Operating Officer C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers officer: Chief Financial Officer 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah director, officer: Chief Medical Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai director, officer: Chief Executive Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West 10 percent owner PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman officer: Chief Financial Officer 65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners officer: Chief Financial Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303